Pilot randomised trial of a brief intervention for comorbid substance misuse in psychiatric in-patient settings by Graham, HL et al.
1 
 
Pilot randomised trial of a brief intervention for co-morbid substance misuse in psychiatric 
inpatient settings  
 
*Dr Hermine L. Graham BSc, ClinPsyD, Dip Cognitive Therapy 
Consultant Clinical Psychologist & Lecturer 
School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK 
Telephone: (+44) 0121 414 7204 
Fax: (+44) 0121 414 4897 
Email: H.L.GRAHAM@bham.ac.uk 
*Author for Correspondence 
 
Prof Alex Copello BSc, MSc, PhD 
School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK 
 
Dr Emma Griffith BSc, MSc, ClinPsyD, Dip Cognitive Therapy 
School of Psychology, University of Bath, Claverton Down, Bath, BA2 7AY, UK 
 
Prof Nick Freemantle PhD 
Department of Primary Care and Population Health, Upper Third Floor, UCL Medical School 
(Royal Free Campus), Rowland Hill Street, London NW3 2PF, UK 
 
Prof Paul McCrone BSc, MCs, PhD 
Health Service and Population Research Department, Institute of Psychiatry, Kings College 
London, London, UK 
 
Latoya Clarke BSc, MRes  
School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK 
 
Kathryn Walsh BSc, MSc 
School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK 
 
Chrysi A. Stefanidou BSc, MSc, PhD 
School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK 
 
Arsal Rana 
School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK 
 
Prof Max Birchwood BSc, PhD, DSc 
Division of Mental Health and Wellbeing, University of Warwick, Coventry, CV4 7AL, UK 
 
Running title: Comorbid substance misuse in psychiatric hospitals 
 
  
2 
 
Abstract 
 
Objective: This proof of principle study evaluated the effectiveness and feasibility of a brief 
motivational intervention, delivered in mental health inpatient settings, to improve 
engagement in treatment for drug and alcohol misuse.   
Method: A randomized controlled trial using concealed randomization, blind, independent 
assessment of outcome at 3 months.  Participants were 59 new adult admissions, to 6 acute 
mental health hospital units in one UK mental health service, with schizophrenia related or 
bipolar disorder diagnoses, users of community mental health services and also misusing 
alcohol and/or drugs. Participants were randomised to Brief Integrated Motivational 
Intervention (BMI) with Treatment As Usual (TAU), or TAU alone.  The BMI took place over a 
2-week period and encouraged participants to explore substance use and its impact on 
mental health.  
Results: 59 inpatients (BMI n=30; TAU n=29) were randomised, the BMI was associated with 
a 63% relative odds increase in the primary outcome engagement in treatment (OR 1.63 
(95% CI 1.01 to 2.65; p=0.047)), at 3 months. Qualitative interviews with staff and 
participants indicated that the BMI was both feasible and acceptable. 
Conclusion 
Mental health hospital admissions present an opportunity for brief motivational 
interventions focussed on substance misuse, and can lead to improvements in engagement.  
 
Keywords: RCT, Hospital admission, dual diagnosis, schizophrenia, substance misuse 
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Significant Outcomes 
 It is both feasible and acceptable for inpatient staff to engage inpatient’s in brief 
motivational interventions focussed on their substance misuse, whilst admitted to 
psychiatric hospitals.  Staff who delivered the intervention found the short burst and 
targeted style a useful method of engaging inpatients. 
 The findings indicate that the brief motivational intervention, delivered during acute 
psychiatric admission, led to improvements in engagement in substance misuse 
treatment. 
 Whilst this is a challenging group of participants to engage it is clear that it is possible to 
recruit and retain participants from this client group and primary outcome data were 
available for 58, highlighting the advantage of a primary outcome measure based on 
assessment by care coordinators. 
 
Limitations 
 This was a pilot feasibility study, which supports the need for a larger trial.  
 Specialist “dual diagnosis” staff delivering the intervention alongside inpatient staff 
provided the latter with an additional level of available expertise, informal in-situ 
supervision and  formed a bridge with care co-ordinators in the community. However, 
the availability of such a resource is limited in routine services and adds organisational 
complexity. 
 Further research will need to test whether the intervention impacts significantly to 
reduce subsequent hospital admissions and substance misuse. 
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Introduction 
 
Hospital admissions may present a natural window of opportunity for inpatients to re-
evaluate behaviours that might negatively impact on their health and mental health (1-3). 
As acute symptoms of mental ill health decline this period may be characterised as a time of 
contemplation and a window of increased awareness and insight into factors that 
contributed to becoming mentally unwell and or being admitted into hospital (4,5).  
Research has shown that, some individuals may “seal over” the experience, in an attempt to 
reduce emotional distress (6). That is, they may deny or minimize recent mental health 
symptoms or experiences and precipitating factors, and as a result, lose awareness of the 
triggers for becoming unwell (6). Sealing over the experience of relapse was found to 
predict low engagement with mental health services six months after discharge for 
psychiatric inpatients (6). Drug and alcohol misuse in those with severe mental health 
problems is widespread (7-10).  It is associated with poor engagement in treatment (11-13), 
low motivation to change (14-16), increased psychiatric hospital admissions (e.g. 17), and  
impacts negatively on the delivery of treatment and management of care during in-patient 
stays (18). Among this client group poor treatment engagement is a barrier for change and 
positive treatment outcomes (12,16,19-20).   
 
Of those admitted into psychiatric inpatient facilities 22-44% have been found to have co-
existing alcohol or drug problems (18). However, drug or alcohol problems and the role they 
may have played in precipitating a psychiatric hospital admission are not routinely 
addressed in such settings. It is recommended that the clinical management strategy of a 
psychiatric admission should involve inpatient staff who are trained in routine assessment 
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and treatment of substance misuse providing simple approaches to enhance motivation to 
change substance use (18). Nonetheless this continues to be a significant gap in service 
provision, re-admissions are high, outcomes for this group remain poor (21,22). There are 
equivocal findings in trials of effectiveness of long-term interventions with psychosis and 
substance misuse (23). However, the evidence for brief motivational-based interventions is 
encouraging (16,24-28) and shows promise in inpatient settings when delivered by trained 
therapists (26; 29-30).   
 
Aims of the Study 
The current study sought to evaluate whether a psychiatric hospital admission represents a 
natural window of opportunity for individuals who misuse substances to be routinely 
offered treatment, by inpatient staff, to re-evaluate drug and alcohol use and become 
aware of negative impacts on mental health. 
 
Method 
Study design and participants 
The study was an open (rater blinded), prospective randomised trial, analysed by intention 
to treat (31). Intention to treat according to ICH E9 is the principle that  
participants are analysed on the basis of the group to which they were 
randomised regardless of the treatment that they actually received.  The trial utilised 
concealed randomisation; blind, independent assessment of outcome at 3-months; 
characterisation of refusers and drop-outs.  Participants were  randomised on a 1:1 basis, to 
one of two experimental conditions: Brief Motivational Intervention (BMI) in addition to 
Treatment As Usual (TAU); or TAU. Participants recruited were: adults aged 18 years or 
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above with an ICD-10 diagnosis of schizophrenia, schizoaffective or delusional disorders 
(F20,22,23,25,28,29); bipolar affective disorders (F31); or recurrent depressive disorder 
(F33.2) (32), service users of community mental health services; new admissions within the 
acute phase of severe mental health problems;  who were identified as misusing alcohol 
and/or drugs over the past month based on a minimum score of 3 (abuse/dependent use 
based on DSM-IV diagnostic criteria for substance-related disorders) on the Clinicians 
Alcohol/Drugs Use rating scale over the past three months (32) and had a Care Co-ordinator 
in a Community Mental Heath Team. Participant’s capacity to consent was  
established by the Responsible Clinical Officer. Participants were recruited from inpatient 
units, within a single UK, National Health Service (NHS) Trust including eleven acute wards 
and three Psychiatric Intensive Care Units (PICUs),  offering a total of 202 beds over a 15-
month period. The trial received ethical approval from the West Midlands –The Black 
Country National Research Ethics Committee (12WM/0369).  
 
The primary hypothesis tested was that Brief Integrated Motivational Intervention (BMI) 
would significantly improve treatment engagement for alcohol and drug misuse compared 
to treatment as usual (TAU). The secondary hypotheses were that those receiving the BMI 
would show greater readiness to change substance use behaviour when compared to those 
receiving treatment as usual and that the BMI would be more cost- effective than the TAU 
due to reduced service utilisation. 
 
Eligible participants were identified by Research staff based on review of care records. A 
screening measure was completed with Care Co-ordinators confirming trial eligibility.  
Within two weeks of admission, once acute symptoms eased, eligible participants were 
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invited to participate. Written information about the study was provided and written 
consent obtained. A battery of assessments was administered. Upon completion, 
participants were randomly allocated to the intervention BMI group (in the context of TAU) 
or the TAU group (the control group).  Just prior to the 3-month data collection meetings 
were scheduled for completion of follow-up assessment battery by blind researchers. 
Participants were not paid for study participation.   
 
Sample size 
A power calculation was done based on a previous study (27) using the primary outcome 
measure: Substance Abuse Treatment scale (SATs).  Allocating 68 particpants by a 1:1 
strategy between the treatment and control conditions (34 participants per group) would 
have 90% power (1-Beta) to find a difference of 1 point on the SATs scale to be statisticaly 
significant, using a conventional two sided Alpha of .05.  A 1 point difference would be 
clinically important for participants and mental health services as it would indicate 
increasing levels of engagement in treatment and addressing substance misuse (eg. a shift 
from "Pre-engagement" to "Engagement").   
 
Randomisation 
The trial used independent central randomisation using a concealed process via e-mail. The 
researchers were blind to participant treatment group allocation until all baseline, post-
treatment and 3-month follow-up quantitative assessments had been completed. 
Researchers were unblinded once the 3-month data collection had been completed.  
Participants in the BMI group then completed a qualitative interview.  
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Trial Interventions 
Brief Integrated Motivational Intervention (BMI) 
The BMI, a ‘Brief Integrated Motivational Intervention’, was offered in the context of TAU, 
guided by a manual designed for purpose, based on key ingredients in the two early phases 
of Cognitive-Behavioural Integrated Treatment (33) strategies from Cognitive therapy for 
substance use (34) and Motivational approaches (35). BMI promoted a conversational style 
to build good collaborative relationships with participants working toward a joint goal of 
“keeping participants from returning to hospital”. The BMI provided a 3-step framework. 
The initial step provided participants with personalised feedback of information gathered in 
the baseline substance use assessment and highlighted potential impacts on health and 
mental health. Participants were provided with tailored psychoeducational material.  The 
second step aimed to help participants make decisions. Strategies were aimed at: increasing 
awareness of perceived “benefits” of use and “costs” associated with continued misuse; re-
evaluation of positive beliefs about substances; building awareness of how substance use 
and mental health interact and maintenance cycles. The third step encouraged participants 
to contemplate change and develop a change plan based on a self-identified goal and 
included strategies to cope with setbacks, cravings and urges and develop social support for 
change. Participants were offered a Peer Mentor during the second step of the intervention 
aiming to  provide ongoing support and solidarity for change.  
 
The BMI was delivered by inpatient unit staff trained as part of the study working alongside 
staff from a specialist “dual diagnosis” Trust-wide service, the COMPASS Programme (36). 
The BMI was delivered over a 2 week period for 4-6 sessions lasting 15-30 minutes each .  A 
“booster session” was arranged to be delivered one month after completion. The booster 
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session aimed to consolidate motivation  and  transfer the skills from the BMI to the 
community and was provided by a member of the specialist team and attended by the 
participant’s community-based Care Co-ordinator.  Staff  training was delivered over two 
days and supported by a treatment manual.  Supervision of the BMI was provided by three 
of the Investigators. Group, face-to face or telephone supervision were delivered. During 
supervision, the standard of delivery was regularly monitored and assessed for fidelity and 
adherence.   
 
Treatment as Usual (TAU) 
Treatment  as usual was provided by nursing and medical staff on the mental health units in 
line with inpatient policies, and is regularly monitored by the UK Care Quality Commission.  
It included assessment and monitoring mental state, provision of medication and 
stabilisation of mental state.  
 
Statistical Methods  
Analysis was carried out using SAS version 9.4 (SAS Institute, Cary NC). The analysis method 
for the primary outcome was a proportional odds model. The proportional odds method 
used included the pre and post intervention periods (L1SATS and L3STATS), included a 
cumulative log log link function and multinomial error, linked within a subject with a 
random intercept term.  Denominator degrees of freedom were derived from the number of 
subjects.  Models used maximum Likelihood with adaptive quadrature.  The appropriateness 
of the proportional odds assumption was assessed using the Score Test. Statistical 
significance was assessed using a conventional two sided Alpha of .05.   The secondary 
outcomes were analysed using analogous generalised mixed models with appropriate link 
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functions and error structures. The ITT principle was used for all analyses. Missing data was 
excluded as it would be inappropriate to impute it because it is most plausibly missing not at 
random. 
 
Cost effectiveness Evaluation 
 
Participant contacts with staff providing the intervention were recorded as well as staff 
supervision time and these were combined with unit costs (37). Other service use was 
measured for the three months pre-baseline and over the post-randomisation period using 
the Client Service Receipt Inventory (38). This recorded use of primary and secondary health 
and social care services. Sources of data included Client self-report and where data could 
not be obtained via self-report and/or specific information was required (e.g. medication, 
appointments, dates of hospital admission) this was gathered via the service electronic 
medical records. Total service costs were compared at baseline and over the post-
randomisation period, the latter adjusting for the baseline costs. The EQ-5D [39] measure 
was used, which is frequently used to produce quality-adjusted life years (QALYs) as part of 
economic evaluations (31). Cost data are frequently skewed and a bootstrap model was 
used which makes no assumption about the underlying cost distribution.  
 
Qualitative Evaluation  
 
Qualitative semi-structured interviews with participants after the 3-month follow-up point 
sought to assess satisfaction with the treatment received and perceived processes of 
change, including helpful aspects of the therapeutic process. A sample of therapists was 
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interviewed using a semi-structured interview, individually and in focus groups.  These were  
recorded, transcribed and  thematic analysis conducted, steps were taken to ensure 
reflexivity (40). That is, attending systematically to the context of knowledge construction by 
examining concepts critically and aiming to eliminate assumptions and preconceptions 
affecting interpretation of findings. This was done through group discussions between the 
analysts, with the wider research team and checking the final findings with some 
participants (40).  
 
 
Outcome Measures 
 
Primary Outcome 
 
The primary outcome was engagement with substance misuse treatment whilst inpatient 
and with community treatment services at 3-month follow-up as reported by Care Co-
ordinators/primary clinician, using the Substance Abuse Treatment Scale (SATS) (14,32)a  
widely used measure with reported high validity, reliability, and test-retest reliability 
(14,32). The Primary Clinicians assessed the level of engagement in substance misuse 
treatment and progress toward recovery from substance use problems, based primarily on 
observable behaviours, on an 8-point hierarchical motivational scale.  The reporting 
timeframe was adapted to the previous 3-months.   
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Secondary Outcome Measures 
 
i) Readiness to change 
Current readiness to change alcohol and drug use was assessed using the 19-item Stages Of 
Change Readiness And Treatment Eagerness Scale (SOCRATES). (41).  
 
Motivation to change was measured by the: Importance-Confidence Ruler which is a global 
assessment of motivation and confidence to change assessing two concepts underpinning 
readiness to change (42); participants were also asked to rate on a scale of 0 to 10 how 
important it was to change the use of the primary substance and how confident they were 
that they would succeed.  
 
ii) Drug Use & Alcohol Use 
Drug and alcohol use was assessed using a number of complementary measures. The 
number of days each substance had been used in the past 30 days and the average amount 
of use of each drug on a using day was assessed using section B of the Maudsley Addiction 
Profile (MAP) (43).  The Clinicians Alcohol/Drugs Use rating scales (CDUS/CAUS) was used as 
a screening tool for inclusion, based on DSM-IV diagnostic criteria for substance-related 
disorders, and reliably used by primary Clinician’s to classify severity of substance use 
amongst people with severe mental health problems (32). The reporting timeframe for the 
AUDIT both at baseline and post-treatment was adapted to the previous 3-months. The 
Severity of Dependence Scale was used to screen for the severity of drug dependence (44-
46). The Alcohol Use Disorders Identification Test (AUDIT) a well validated 10-item self-
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report questionnaire was used to investigate alcohol consumption (47,48).  
 
 
iii) Psychological Functioning 
Psychological Functioning was assessed using 3 measures:  Recovery Style Questionnaire 
(RSQ) is a 39-item self-report measure designed to assess two concepts of recovery from 
mental health relapses; ‘Integration’ (i.e. acknowledgement of, openness and attempts to 
cope with the mental health problem), and ‘Sealing-over’ (i.e cognitive and behavioural 
attempts at avoiding the diagnosis and experience of mental health problems).   It reliably 
enables four recovery styles to be classified based on a continuum (i.e. ‘Integration’; ‘mixed 
picture in which integration predominates’; ‘mixed picture in which sealing-over 
predominates’ and ‘sealing- over’(49)); Insight Scale (IS) reliably assesses changes in levels of 
insight in terms of perceived need for treatment (50); HADS a 14-item self-report measure 
found to reliably assess anxiety and depression (51, 52).  
 
 
Results 
 
60.67% (1345/2217) of inpatients screened were using substances. However, 1286 did not 
meet the other study criteria or declined to be involved in the study. 44%, (872/1976) of 
inpatients were not misusing substances or their substance use was not recorded (Figure 1).  
Fifty nine inpatients were recruited from 14 wards (Acute n=50; PICU n=9) and randomised 
to BMI n=30 or TAU n=29. Table 1 shows baseline characteristics of the participants who 
had a mean age of 38.6 years, with a schizophrenia diagnosis, primarily misusing cannabis, 
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or alcohol. Inpatients (N=123) were approached regarding involvement in the study, the 
characteristics of those who consented compared to refusers (n=64) (52%) appeared similar 
in age, sex and type of mental health team. All participants were followed up for the 
primary outcome at 3-months, one participant was withdrawn due to risks. Fifty (85%) study 
participants were interviewed at 3-month follow-up.  
 
The Intervention 
Twenty seven inpatient staff from all wards and six specialist staff were trained to deliver 
the BMI, 12 inpatient staff and 5 specialist staff actually delivered the MI. Twenty one of the 
30 (70%) participants in the BMI group received the intervention.  The 9 participants who 
did not were; discharged prior to the first session (n=5), refused the intervention (n=3) and 
sent on home leave (n=1).  The mean exposure for participants who received the 
intervention was 3.14 (SD 1.92) sessions, (range1-5 sessions). Mean duration of sessions was 
18.3 minutes (SD 4.90). The average total mean duration of the intervention was 57.6 
minutes (SD 31.33). The booster session was completed for nine (30%) of these participants.  
Two participants received a session with a Peer Mentor who aimed to provide ongoing 
support and solidarity for change. The Peer Mentor provided some low-key social support 
and a listening ear to help participants feel less isolated and more connected to others 
during a challenging time and to generally see how they were finding the intervention. 
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Figure 1: CONSORT Diagram of Trial profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 Did not meet inclusion criteria: No substance misuse/Substance use not recorded (n=872), 
Use substances but not other inclusion criteria (n=1104) (Inclusion criteria not met due to 
either, mental health, care co-ordinator unavailable/unallocated, rating unavailable, 
discharged prior to rating, language, mental health capacity, care being transferred to or from 
another service. 
2
Other: includes previously consented (n=6), previously refused (n=15), 
previously withdrawn (n=1), discharged before rating (n=30), unable to rate (n=28), 
discharged before met (n=32), not randomized – withdrawn (n=4), not randomized – 
discharged (n=2).
 
Analysed  (n=30) 
 
 
Analysed  (n= 28) 
 Excluded from analysis (n=1 ) 
Reason (Withdrawn from trial due to 
risk ) 
 
 
Assessed for eligibility (n=2217)  
Excluded (n=2158): 
 Did not meet criteria
1
 (n=1976) 
 No substance misuse/ not recorded (n=872)  
Use substances but not other inclusion 
criteria (1104)  
Declined to participate (n=64): Other 
2
(n=118)
 
 
Other reasons
2
 (n=118) 
 
 
 
 
Lost to follow-up at 3 months  (n=0) 
Allocated to intervention (n=30) 
 Received allocated intervention (n= 21) 
 Did not receive allocated intervention (n= 9) 
Discharged prior to intervention (n=7) 
  Refused intervention (n=2) 
Lost to follow-up at 3 months (n=1) 
Withdrawn (n=1) 
 
Allocated to treatment as usual (n=29) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=59) 
Enrollment 
16 
 
Table 1. Baseline Characteristics of Participants 
 
 
TAU 
(n=29) 
BMI 
(n=30) 
Age 
  
Mean (SD) 37.69 (11.11) 39.5 (11.12) 
   
   
Sex 
  
Male (%) 25 (86.2) 25 (83.3) 
   
Diagnosis 
  
Schizophrenia (%) 19 (65.5) 17 (56.7) 
Schizoaffective Disorder (%) 2 (6.9) 3 (10) 
Psychosis (%) 1(3.4) 0 (0) 
Bipolar affective Disorder (%) 7(24.1) 10 (33.3) 
Primary Substance 
  
Alcohol (%) 11 (37.9) 12 (40) 
Cannabis (%) 13(44.8) 14 (46.7) 
Crack (%) 0 (0) 1 (3.3) 
Cocaine (%) 2 (6.9) 0(0) 
Methadone (%) 1 (3.4) 0(0) 
Legal Highs (%) 2 (6.9) 2 (6.7) 
Diamorphine (%) 0 (0) 1(3.3) 
Ethnic origin 
  
White British (%) 15(51.7) 7(23.3) 
White Irish (%) 2 (6.9) 4 (13.3) 
Asian Indian (%) 2(6.9) 0 (0) 
Asian Pakistani (%) 1(3.4) 4(13.3) 
Asian Bangladeshi (%) 1(3.6) 0 (0) 
Asian Other (%) 1(3.4) 1(3.3) 
Black Caribbean (%) 4 (13.8) 8(26.7) 
Black African (%) 2 (6.9) 0 (0) 
Black Other (%) 0 (0) 1 (3.3) 
Mixed Caribbean (%) 0 (0) 5 (16.7) 
Mixed African (%) 1(3.4) 0 (0) 
Housing status 
  
Live alone (%) 16 (55.2) 16 (53.3) 
With parents or guardian (%) 5 (17.2) 9 (30) 
With partner (%) 3(10.3) 0 (0) 
Other (%) 5 (17.2) 5 (16.7) 
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Primary Outcome 
 
Engagement with Substance misuse Treatment 
At baseline, for both groups engagement could be described as not having regular contact 
with an assigned case manager. Both groups had shifted at follow-up, indicating regular 
contacts with a case manager and discussing substance use and showing evidence of a 
reduction in use. The effect of randomisation to the BMI group rather than TAU was 
described using the odds ratio where a value greater than 1 indicates a benefit for the 
intervention.  Two TAU SATs values were missing, one at baseline the other at follow-up. 
The intervention was associated with a 63% relative odds increase in the SATs score, which 
is conventionally modestly statistically significant (OR 1.63 (95% CI 1.01 to 2.65; p=0.047)) 
(see Table 2).  In supportive analyses the relationship between actual length of stay in 
hospital and response to the intervention in relation the primary outcome was examined. 
There was no interaction between time in hospital and treatment effect. 
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Table 2.  Difference in SATs, Number of substances used, Days Using and HADS at 3-month 
follow-up by randomised condition, conditional on baseline assessment 
Outcome 
Odds Ratio¥ 
(95% CI) 
Relative Riskⱡ 
(95% CI) 
 
Difference in means≠ 
(95% CI) 
 
 
P Value2 
 
SATs 1.63 (1.01 to 2.65) - - 0.047* 
Number of 
substances used 
0.66 (0.33 to 1.33) - - 0.240 
Number of days 
using primary 
substance 
- 1.02 (0.82 to 1.26) - 0.854 
HADS     
Anxiety - - -0.80 (3.93 to 2.34) 0.611 
Depression - - -1.89 (-4.51 to 0.74) 0.156 
Insight Scale     
Awareness of 
Symptoms 
- - 0.03 (-0.70 to 0.75) 0.944 
Awareness of 
Illness 
- - 0.25 (-0.42 to 0.93) 0.459 
Need for 
Treatment 
- - 0.09 (-0.65 to 0.84) 0.802 
Total - - 1.03 (-0.49 to 2.54) 0.178 
2two-tailed; *p<0.05; ¥ Mixed proportional odds model; ⱡ Poisson mixed model; ≠ Gaussian 
mixed model 
 
 
Secondary Outcome Measures 
Readiness to change 
For the secondary outcome, readiness to change, both groups remained in the ‘low’ 
readiness to change category for alcohol and drugs at follow-up. No overall statistical 
analysis was carried out for this readiness to change data, due to missing data and the 
scores for alcohol and drug use could not be meaningfully combined. Assessment of 
motivation to change indicated that both groups at baseline similarly rated the Importance 
to change their substance use (BMI=6.77(SD 3.23); TAU=7.19(SD 3.58)) and Confidence to 
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be able to change (BMI=8.12(SD 2.30); TAU=7.50(SD 2.94)).  There was very little variation 
between Importance (BMI=7.08(SD 3.74); TAU=6.89(SD 3.30)) and Confidence  
(BMI=8.15(SD 2.19); TAU=8.02(SD 2.83)) scores across time and between groups. 
 
 
Substance Use 
 
Number of days Substances Used 
The number of days in the past 30 in which the primary substance consumed was available 
for 50 subjects at baseline and follow up. Both groups reduced number of days they used by 
more than half (Table 3). There was no evidence of an effect of randomised treatment on 
the number of days using the primary substance (Relative Risk 1.02 (95% CI 0.82 to 1.26; 
p=0.85)) (Table 2).     
 
Table 3. Substance Use in past 30 days at baseline and follow up 
                                                 
BMI 
 
                                        TAU 
   Baseline 
 (n=30) 
Follow-up 
(n=26) 
Baseline 
(n=29) 
Follow-up 
(n=24) 
Number of 
Substances 
     
None  0 10 0 5 
One  14 10 18 16 
Two  12 6 7 3 
Three  4 0 3 0 
Four  0 0 1 0 
Number of 
days used 
     
Mean  
(SD) 
 21.48 
(11.00) 
9.25 
(10.82) 
21.23  
(9.68) 
9.31  
(11.86) 
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In supportive analysis the amount of substance used was explored. At 3-month follow-up, 
15 participants reported not having used any substances in the past 30 days; 10 of whom 
were in the BMI group compared to 5 in TAU (Table 3). The number of substances used by 
the BMI group reduced on average by 0.34 or about a third of a substance when compared 
to the TAU group (Table 2).  However the effect was not significant (OR 0.66 (95% CI 0.33 to 
1.33; p=0.24)).     
 
Severity & Impact of Substance Use 
Mean baseline scores for the primary substance used for both groups, as rated by the Care 
Co-ordinator, was categorised as ‘abuse’ in the previous three months (Table 4).  Mean 
AUDIT scores for the TAU and BMI group met the ‘possible dependence’ category at 
baseline. At 3-month follow-up these mean scores were lower and were within the 
‘increasing risk category’. Mean SDS scores across time and groups were all above a score of 
4 which suggested a continued ‘level of dependence’. 
 
Table 4. Severity & impact of Primary substance at baseline & 3 month follow up  
 TAU BMI 
 Baseline Follow-up Baseline Follow-up 
Alcohol (CAUS) N=11 N=11 N=12 N=12 
Mean (SD) 3.27 (0.65) 2.18 (.98) 3.42 (0.67) 2.25 (1.22) 
Drugs (CDUS) N=18 N=17 N=18 N=18 
Mean (SD) 3.28 (0.46) 2.41 (1.06) 3.33 (0.49) 1.89 (0.90) 
Alcohol Use (AUDIT) N=11 N=11 N=12 N=9 
Mean (SD) 20.00 (8.14) 13.09 (7.92) 22.00 (7.76) 15.11 (7.71) 
Drug Use (SDS) N=18 N=13 N=18 N=14 
Mean (SD) 5.11 (4.93) 5.31 (3.68) 4.56 (4.23) 4.64 (4.18) 
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Psychological Functioning 
 
Anxiety & Depression 
Analysis of the difference in the HADS Anxiety and Depression Scores by randomised group, 
accounting for baseline values, indicated no evidence of a treatment effect on HADS Anxiety 
(Difference in means -0.80(95% CI 3.93 to 2.34; p=0.611)). The HADS Depression, although 
not significant, was in line with a modest effect on that outcome suggesting that the TAU 
had higher depression scores (Difference in means -1.89 (95% CI -4.51 to 0.74; p=0.156)) 
(Table 2).  
 
Style of Recovery from Mental Health Problems 
Baseline mean scores on the RSQ descriptively classified the TAU group as adopting a ‘mixed 
picture in which integration predominates’ style of recovery from mental health problems 
(66.54 (SD 15.28)), and the BMI group as adopting an ‘integration’ style (71.14 (SD 13.37)). 
At 3-month follow-up both groups were classified as ‘integration’ (TAU=70.74 (SD 70.74); 
BMI=71.15(SD 18.97), suggesting that both groups had an acknowledgement of and were 
making attempts to cope with their mental health problems.  Due to the amount of missing 
data no further analysis was conducted. 
 
Insight in Mental Health problems 
Awareness of symptoms and of illness mean scores indicated ‘poor insight’ over time in 
both TAU groups at baseline and follow-up. Need for treatment mean scores increased over 
time for both groups suggesting ‘good insight’ into need for treatment.  The difference in 
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means implied a benefit for the intervention. Whilst there were no significant differences all 
values pointed toward a benefit from the BMI (see Table 2). 
 
Cost effectiveness Evaluation  
For the secondary outcome of cost-effectiveness, service use in the period prior to baseline 
was relatively similar between the two groups. All participants were inpatients during the 
baseline period and all but one were also inpatients during the post-randomisation period 
(one participant in the BMI group went on home leave on the day of randomisation). 
Although we do not test for differences for individual services it was observed that during 
the post-randomisation period there was a greater number of participants in contact with 
psychiatrists in the BMI group (BMI n=19; TAU n=13) and more participants in contact with 
assertive outreach teams (BMI n=7; TAU n=1). At baseline, the number of days in hospital 
was similar between the groups (BMI=13.4 (SD 7.9); TAU=14.5 (SD 9.7). During the post-
randomisation period inpatient days were slightly higher in the BMI group (BMI=45.3 (SD 
35.1); TAU=35.8 (SD 30.8). The mean cost of delivering the intervention was £72 (SD £66). 
The total mean cost of services used post-randomisation by the TAU and BMI group were 
£15,698 (SD £12,632) and £18,651 (SD £15,580) respectively. Adjusting for baseline costs, 
the BMI group had costs that were on average £3279 higher post-randomisation than the 
TAU group (95% CI, -£3933 to £10,876). One participant in the BMI group was an outlier in 
number of days of inpatient care during the post-randomisation period. When they were 
removed the mean cost for the BMI group was £16,825 (SD £12,159) The EQ5D-5L scores 
were similar between the two groups.  
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Qualitative Evaluation  
 
Two focus groups (n=7) and five individual interviews were conducted with staff who 
delivered the BMI. Twenty-one participants who received the intervention were interviewed 
at follow-up.  Qualitative data revealed that participants and staff found the BMI both 
feasible and acceptable when delivered as part of routine care on inpatient wards. Whilst 
most participants reported on positive non-specific factors of the intervention; such as ‘staff 
giving time’ and ‘going out of their way’, several participants identified that the intervention 
allowed them to recognise the amount of substances they were using, the pros and 
cons/effects of their use on them or their mental health, as well as developing new coping 
strategies and techniques. For inpatient staff and the specialist practitioners the targeted, 
motivational style of the intervention and the brevity of the sessions were found to be 
useful to engage patients in discussions about their substance use. There were mixed views 
about the timing of the intervention and how well it worked when inpatients were acutely 
unwell; other issues included the practicalities of joint working between inpatient and 
community-based staff; and conflict with duties on the ward. 
 
Discussion 
 
The intervention was associated with an improvement in engagement in treatment, the 
primary outcome, which was modestly statistically significant providing some support for 
the principal hypothesis in line with findings in out-patient settings (e.g. 27). During the 
post-randomisation period there were greater rates of contacts with psychiatrists and 
assertive outreach teams among inpatients who received the intervention. A shift was 
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observed from irregular to regular contacts with care co-ordinators, discussing substance 
use. Both groups fell into the ‘low’ readiness to change category at follow-up and there was 
no significant difference in the reduction in the number of days on which the primary 
substance was used between groups. However, both groups reported a reduction by more 
than half in the number of days they used their primary substance over the past 30 days at 
3-month follow-up.  These changes in substance use noted in both groups, are not an 
uncommon findings in studies evaluating motivational based interventions. A number of 
explanations have been offered including the natural fluctuations in co-existing mental 
health and substance misuse and the period before an admission being associated with 
greater amounts of substance use resulting in relative improvement that may not 
necessarily reflect longer term improvements; also it has been suggested that the baseline 
assessment of both groups may have a motivational effect (e.g. 53-55).   Some exploratory 
non-significant findings that warrant investigation in a larger trial are reductions in the 
number of substances used.  A study by Baker and colleagues carried out in inpatient 
settings similarly found that brief motivational interventions had the potential to have a 
modest, short-term impact on poly-drug use (56). Tobacco smoking was not assessed in the 
current study; however, this would be an important consideration within future research 
due to its prevalence and impacts in this population.  
 
The study aimed to assess the feasibility and acceptability of delivering a brief integrated 
motivational intervention to inpatients as part of routine care on the wards. The 
recruitment rate in the current study was 50%, which was expected among this group of 
service users who have been historically described as ‘difficult to engage’ (11-14, 27).  
However, 85% of participants were retained in the study at follow-up and 70% of 
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participants engaged in the BMI with a good level of exposure to it. Inpatients described the 
intervention as helpful enabling them to: have an opportunity to talk to inpatient staff, 
recognise the amount of substances they were using and the effects of their use on them 
including their mental health. Developing new coping strategies and techniques was also 
helpful. This study indicates that it is feasible and acceptable to engage and retain 
inpatients, with severe mental health problems from a diverse range of ethnic origins, who 
are poorly engaged in treatment and misusing a range of substances in a brief intervention 
for substance misuse, whilst they are on a psychiatric wards.  There was improved 
awareness in both groups over time of the need for mental health treatment and a positive 
shift to a more integrating style of recovery from mental health problems which has been 
associated with improved engagement in treatment over time (6).  The intervention was 
relatively low-cost and no significant differences were observed in costs between the two 
groups. The rate of substance use in the inpatient sample was 61%. However, despite the 
reported rates prevalence of substance misuse amongst those with severe mental health 
problems in the literature and in the current study, a number of inpatients in the current 
study were unable to be included for a number of reasons. Key factors appeared to be 
whether information about substance use was reported and how it was reported and the 
stringent study inclusion criteria needed due to the nature of a randomised controlled trial.  
These factors have important implications for clinical practice and a further trial.  Some of 
the eligible inpatients who refused to participate were poorly engaged with services and 
with their inpatient care and treatment; some were reluctant or suspicious of engaging in a 
research study to discuss their substance use.  Future research might also consider 
strategies to increase the participation rate among eligible inpatients, including payment for 
participation and intervening earlier on during an admission. 
26 
 
 
 
Unlike previous studies (26; 29-30), the current study utilised routine inpatient staff to 
deliver the intervention.  They reported that the short burst and targeted style of the 
intervention was a useful method of engaging inpatients in discussions about drug and 
alcohol use.  However, they felt that the timing (i.e. when such an intervention is delivered) 
was important due to the mental state of inpatients on acute wards.  Similarly participants 
felt that sometimes they did not have the “headspace” and so the timing of the intervention 
appears important.  The qualitative findings highlight that a shift in the clinical management 
strategy on wards would be needed for such brief interventions to become embedded into 
routine practice (57, 58). The literature on inpatient psychiatric treatment has highlighted 
the need for ‘protected time’ for staff to deliver therapeutic interventions as a routine part 
of their inpatient work (59-61).   
 
Specialist “dual diagnosis” staff delivering the intervention alongside routine inpatient staff 
provided an additional level of available expertise and informal supervision in-situ. 
However, the availability of such a specialist resource is limited and adds another layer of 
organisational complexity. None-the-less, the recommendations from other studies for co-
morbid severe mental health and substance misuse problems are that brief interventions 
are best provided within the context of a comprehensive package of ongoing integrated 
treatment (e.g. 27,62) and the specialist staff were able to form a bridge with care co-
ordinators in the community. In future trials the BMI may benefit from evaluation as part of 
a comprehensive package of integrated treatment so that positive changes in engagement 
can be built upon in community services post-discharge. 
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This proof of principle study attempted to test the BMI, method and measures in an 
inpatient setting and there are aspects that would require refinement for further studies. 
There were recruitment challenges; the original protocol aimed for recruitment of 68 
participants, in the event we recruited 59. Whilst a challenging group of participants to 
engage, it is clear that it is possible to recruit and retain participants from this client group 
and primary outcome data were available for 58 highlighting the advantage of a primary 
outcome based on an assessment by care coordinators. However, although these primary 
Clinicians would have been blind at the baseline and two-week ratings, potentially they 
were not at the 3-month rating for those in the intervention arm. This is a limitation of the 
study that may have introduced bias. In addition, a rating of this nature, provided by the 
Primary Clinician working with the client might be influenced by the therapeutic alliance. 
Measuring motivation to change raised a number of challenges, including the sensitivity of 
the measures to differentiate between those who are abstinent or have made changes in 
substance use compared to those who are pre-contemplators. The low uptake of Peer 
mentors requires further consideration in future research. The low number of female 
inpatients included in the study may well reflect that co-existing severe mental health and 
substance misuse is more common among men and less prevalent among females.  It is also 
questionable whether an improvement in costs and health-related quality of life over a 3-
month time period would be found. A future trial should include a sufficiently long follow-up 
to explore cost changes over a prolonged period. In particular, long enough to detect 
differences in readmission rates and assess changes in substance misuse. However, this pilot 
feasibility study suggests that an acute psychiatric hospital admission may present a 
“teachable moment” similar to that identified in physical health settings (1, 63); that is a 
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natural window of opportunity for inpatient staff to routinely engage inpatients in brief 
motivational interventions focussed on alcohol and drug use.  The intervention is feasible 
and represents a simple, low-cost, and easy to implement approach, however, timing is key. 
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